A report highlighted how Wall Street’s “shell” vehicle market has revived in biotech, with reverse mergers more than doubling year-over-year amid investor demand for public listings. Dealmakers cited the speed and access to Nasdaq-style liquidity as the practical advantages driving private biotechs toward reverse transactions. The dynamic comes as IPO activity rebounds, but investors are increasingly cautious about finding high-quality shells. Analysts warn that a shortage of suitable vehicles could become a bottleneck for early-stage financing, shaping which programs get capital and what assets advance. The piece also noted liquidity pressure earlier in the cycle, with emerging biotechs holding shorter cash runways, making rapid public access more attractive. If sustained, reverse mergers could influence timelines for fundraising, trial execution, and capital markets visibility. Overall, the activity suggests that commercialization and funding pathways in biotech are being redesigned around market access rather than only traditional underwriting cycles.